← Oncology Approval Tracker

FDA DECISION ·

Talvey

talquetamab-tgvs · Janssen Biotech

Accelerated approvalNew therapyMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with relapsed or refractory multiple myeloma after at least four treatment lines, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 antibody.

LAMPGEN ANALYSIS

Why it matters

This accelerated approval introduced a GPRC5D-directed T-cell engager for heavily pretreated myeloma.

What research teams should watch

Plan step-up dosing, toxicity observation and follow-up for oral and nutritional effects.

PRIMARY RECORDS

Sources